China's Novo Nordisk Oral Wegovy Filing Accepted

China’s health regulator’s acceptance of Novo Nordisk’s oral Wegovy application adds a regulatory catalyst as the country eyes a surge in GLP-1–based obesity and diabetes treatments. Novo Nordisk is racing with Eli Lilly and others to capture a growing market for pill-based GLP-1 therapies, aiming to complement injections as demand expands. Analysts project China’s obesity burden could reach 65% of the population by 2030, underpinning a multi-billion yuan opportunity for global drugmakers. Eli Lilly has already moved to China with orforglipron, while Novo Nordisk seeks to establish Wegovy’s oral footprint worldwide as competition intensifies. Industry projections estimate GLP-1 weight-management sales in China could rise from a few billion yuan to around 30 billion yuan in five to seven years, reshaping market leadership. The broader effort to offer daily oral options is designed to attract patients who prefer non-injection regimens amid a rapidly expanding Chinese market for obesity and related therapies.